Low-dosage esterified estrogens opposed by progestin at 6-month intervals

Area of Science:

• Reproductive Endocrinology
• Menopause Management
• Pharmacology

Background:

• Standard hormone replacement therapy (HRT) regimens involve monthly cyclic estrogen and medroxyprogesterone acetate (MPA).
• Concerns exist regarding endometrial hyperplasia and bleeding patterns with continuous or standard cyclic HRT.
• Alternative dosing strategies are being explored to optimize safety and efficacy in postmenopausal women.

Purpose of the Study:

• To evaluate the incidence of endometrial hyperplasia, vaginal bleeding, and menopausal symptoms.
• To assess the safety and tolerability of switching from standard HRT to a half-strength estrogen regimen opposed by MPA every six months.
• To determine the impact of this regimen on menopausal symptom control.

Main Methods:

• A cohort of 138 women aged 55-75 years using standard HRT were switched to a lower-dose regimen: esterified estrogens (0.3 mg/day) with 14-day MPA (10 mg/day) courses every six months.
• Endometrial biopsies were performed after one year to assess for hyperplasia.
• Vaginal bleeding was self-reported daily, and menopausal symptoms were assessed using the Greene Menopause Symptom Index.

Main Results:

• Endometrial hyperplasia occurred in 1.6% of women (2/125) after one year.
• Scheduled bleeding was reported by 44% of women, while unscheduled bleeding occurred in 9.4%.
• Vasomotor symptoms improved, with 17% reporting significant improvement at 12 months.

Conclusions:

• A reduced-dose HRT regimen of estrogen opposed by MPA every six months is safe for women aged 55 and older.
• This regimen effectively controls menopausal symptoms while minimizing vaginal bleeding.
• The low incidence of endometrial hyperplasia supports the safety of this modified HRT approach.